The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2024 | Reducing steroid usage in the treatment of lower-risk GvHD
James Ferrara, MD, DSc, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, discusses how clinicians can improve the treatment of graft-versus-host disease (GvHD). GvHD is becoming increasingly lower-risk, so Dr Ferrara recommends minimizing steroid use. He proposes using risk stratification with clinical features and biomarkers to identify lower-risk patients suitable for lower steroid doses. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
I hold a patent for serum biomarkers of acute GVHD which is licensed and for which I receive royalties.
